Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test predict lupus in children with ITP?

NCT ID NCT07680010

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study looks at children with immune thrombocytopenic purpura (ITP) who also have certain antibodies, as they are at higher risk of developing lupus. Researchers will analyze blood samples to track immune cell changes and markers that may signal the transition to lupus. The goal is to better understand how lupus begins and find ways to prevent it in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal early warning signs of lupus in children with ITP, pointing toward ways to prevent lupus before it starts.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate prevention strategies, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 105 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Oct 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion criteria: * For patients : * Child or adolescent with newly diagnosed ITP or SLE according to the specific definitions of ITP or SLE, prior to any treatment, * Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg. * Written consent from parents or guardians, * Patient affiliated to a social security scheme. * For controls : * Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg. * Follow-up in the day hospital at the Bordeaux University Hospital, for a condition that does not affect the immune system * Matched on age, * Written consent from parents or guardians, * Patient affiliated to a social security scheme * Exclusion criteria: * For patients : * ITP secondary to a known cause: previous or concomitant immune deficiency, bone marrow or organ transplantation, other autoimmune disease, Evans syndrome (autoimmune hemolytic anemia or autoimmune neutropenia present at ITP diagnosis) or cancer with immunosuppressive therapy. * Treatment with immunomodulation or immunosuppressants (including immunoglobulins, corticoids, hydroxychloroquine), started prior to inclusion (day of sampling). * Pregnant women, women in labour and breastfeeding women * For controls : * Suffering from an immunological disease, * Infection within fifteen days prior to inclusion, * Immunomodulatory therapy. * Pregnant women, women in labour and breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune thrombocytopenic purpura (ITP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immune thrombocytopenic purpura (ITP) Systemic lupus erythematosus (SLE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Toulouse - Hôpital des Enfants

    Toulouse, 31026, France

  • Chu de Bordeaux- Groupe Hospitalier Pellegrin - Hôpital des Enfants

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.